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This was a 3-year ‘‘real-life’’ study, during which patients’ medication was increased and
decreased to achieve sustained asthma control. Patients (282) were randomised to receive
treatment with SAL 50 mg, FP 250 mg, or SFC 50/250 mg via a Diskus inhaler, bid. A 12-month
double-blind period was followed by a 2-year open phase. The physician increased or decreased
patients’ medication to achieve and maintain asthma control at regular clinical assessments
using criteria based on the asthma treatment guidelines. On completion 73% (168/229) of the
subjects were receiving SFC to maintain control of their asthma, compared with 21% (49/
229) receiving FP and 5% (12/229) receiving SAL. Odds ratio for requiring increased treatment
were 2.66 (pZ 0.002) for patients initially randomised to FP and 9.38 (p < 0.0001) SAL,
compared with SFC. Time until 25% of patients first required an increase in study medication
was 6 months for patients initially treated with SAL compared to 12 months for FP and
21 months for SFC. Symptoms and use of rescue medication improved first, followed rapidly
by PEF with the greatest improvements occurring over the first year. Airway hyperresponsive-
ness continued to improve throughout the study. The majority of patients achieved and main-
tained control of asthma over a 3-year period with physician-driven medication changes.
Patients treated with SFC were more likely to achieve control than patients treated with FP
or SAL alone. Continuing improvements in airway hyperresponsiveness indicate the importance
of maintaining treatment after clinical control of symptoms and lung function are achieved.
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Asthma control in ‘‘real life’’ 349Introduction between the highest and the second lowest PEF reading inAsthma is a chronic inflammatory disease of the airways.
Airway inflammation is associated with airway hyper-
responsiveness, airflow limitation and respiratory symp-
toms. Inflammation and airway hyperresponsiveness often
remain present even in the absence of symptoms.1,2
The goal of asthma management3 is to maintain control of
the disease. This can be achieved by alleviating symptoms,
improving pulmonary function to as close as possible to
normal levels, maintaining normal activity levels and pre-
venting asthma exacerbations, while avoiding adverse
effects from asthma medications. Regular pharmacological
treatment is recommended for the management of all
patients with persistent asthma, and inhaled corticosteroids
are the preferred initial controller treatment for patients
with mild persistent asthma. Treatment with inhaled corti-
costeroids significantly reduces the pathological signs of
airway inflammation4e6 and prolonged treatment improves
airway hyperresponsiveness.7,8 For patients with moderate
to severe persistent asthma, treatment with long-acting
beta-agonists in combination with inhaled corticosteroids is
advocated. Several studies have demonstrated that better
asthma control can be achieved with a combination of
inhaled corticosteroids and long-acting beta-agonists than
with a higher dose of inhaled corticosteroids.9e14
A recent study15 has demonstrated that in a carefully
controlled clinical trial setting guideline-defined control of
asthma can be achieved in the majority of patients by
stepping up treatment to abolish symptoms and restore
normal lung function. Significantly more patients achieved
control with combined inhaled corticosteroid and long-
acting beta-agonist than with inhaled corticosteroid alone,
and control was achieved earlier and at a lower cortico-
steroid dose with the combination treatment. Furthermore,
this high level of control was maintained in a large majority
of patients for up to a year when treatment was maintained
at a constant dose. However, little information is available
on the effects of maintaining asthma control over a longer
time period or whether even better effects could be ach-
ieved with further dosage modifications.
The present report is a 3-year study of asthma control in
a ‘‘real-life’’ clinical setting, during which patients’ medi-
cation was increased and decreased to achieve sustained
control of their asthma. The first year was blinded, and
results for the first year blinded treatment comparison have
been reported previously.16
Materials and methods
Study subjects
Mild to moderate asthmatic subjects (18e70 years of age)
were recruited from a cohort of approximately 4000 asth-
matics, who had previously participated in large epidemi-
ological studies (OLIN studies) in Sweden.17e20 Eligible
patients had reported asthma symptoms or use of rescue
medication at least twice a week, and had either meth-
acholine reactivity (PC20) of 8 mg/mL, diurnal variability
in peak expiratory flow (PEF) of 20% on >3 days during the
last 14 days of the run-in period, or a 30% differencea week, or an increase 15% in forced expiratory volume in
1 s (FEV1) or PEF after inhalation of 0.8 mg salbutamol.
16
Patients previously treated with less than 1200 mg budeso-
nide per day were eligible to enter the study.
The study was conducted by a team of two physicians
and two nurses in four closely-associated clinics in Northern
Sweden. Each of the study clinics was located close to the
neighbourhood of the patient’s home.
The study was performed in accordance with the
Declaration of Helsinki, and all patients provided written
informed consent to participate. The ethical committee at
the University Hospital of Northern Sweden approved the
study.
Study design
This was a 3-year study, in which a 12-month, randomised,
double-blind period16 was followed by a 2-year open period.
Patients with mild to moderate asthma were initially rand-
omised to either salmeterol/fluticasone propionate combi-
nation (SFC), salmeterol (SAL) or fluticasone propionate
(FP) as monotherapy. The study was intended to reflect
normal ‘‘real-life’’ clinical practice as closely as possible
and the physician adjusted patients’ medication to achieve
and maintain asthma control. The aim of treatment was to
free subjects from asthma symptoms, exacerbations, rescue
medication use, and the need for sick leave, and to
normalise their lung function. We also investigated the long-
term changes in airway hyperresponsivness.
Patients were randomised, after a 2-month run-in
period, during which they received a maximum dose of
budesonide 400 mg/day or equivalent, to receive blinded
treatment with SAL 50 mg, FP 250 mg, or SFC 50/250 mg via
a Diskus inhaler, twice daily for 12 months. Subjects
whose asthma was not controlled had their treatment
increased with an additional dose of FP 250 mg twice daily
(i.e. patients on SAL were changed to SFC 50/250 mg,
patients on FP had their dosage increased to FP 500 mg, and
those on SFC had their dosage increased to 50/500 mg), and
entered the open-label phase of the study. Patients who
remained controlled continued with blinded treatment for
12 months16 before entering the 2-year open phase.
During the open phase, treatments were adjusted by the
investigating physician, as necessary, to achieve and
maintain asthma control (Fig. 1). The need for treatment
changes was evaluated by the investigating physician based
on the patient’s clinical history since the previous study
visit. Patients medication was increased after an exacer-
bation. Medication was also increased when a patient
experienced either night symptoms on more than one
occasion during a 2-week period, day symptoms more than
2 days in 1 week, the use of rescue mean medication on
over 2 weeks more than 2 days in 1 week, a decrease in
morning PEF and/or clinic FEV1 of greater than 10%.
Patients were assessed every 3 months during the first
2 years of the study and 6-monthly during year 3.
Methods
Patients completed daily record cards during the 2 weeks
preceding each clinic visit, on which they recorded morning
Figure 1 Study design: possible dosage adjustments during
open phase.
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cation (salbutamol) use and adverse events. Patients were
instructed to contact the clinic by telephone if they expe-
rienced deterioration of their asthma symptoms between
visits. Such contacts were followed up and assessed for
appropriate intervention by the investigating physician.
Patients’ compliance with their medication was assessed by
the investigating clinic staff at each clinic visit by ques-
tioning patients and also assessment of the number of doses
recorded on the patients’ inhalers. Patients who did not
comply with at least 70% of their medication doses were
withdrawn from the study.
FEV1 was measured at the scheduled clinic visits. Airway
hyperreactivity to methacholine21,22 was assessed at base-
line and after 12, 24 and 36 months of treatment; the
concentration of methacholine which provoked a 20% fall in
FEV1 (PC20) was recorded.
The physician assessed each patient’s asthma control
and need to increase or decrease their medication at the
clinic visits. These clinical assessments were based on
patients’ self reporting of symptoms, exacerbations and use
of rescue medication, in addition to diary card data and
clinic spirometry. Criteria for asthma control and the need
to increase medication were based on the goals of treat-
ment outlined in asthma treatment guidelines3,16 and
included normal lung function, no exacerbations and few
symptoms. Study medication dosage was decreased when
patients’ asthma remained controlled for a period of
6 months if considered appropriate by the physician (less
than one episode of symptom per month). Patients’ medi-
cation could be changed at more than one clinic visit during
the study.
Safety was assessed by recording adverse events
throughout the study, from diary card recordings and any
events assessed at the clinic visits. Serum cortisol concen-
trations were measured at baseline, and at 1, 2 and 3 years
after start of treatment and any significant changes were
reported as adverse events.
This study was designed and planned by the OLIN
investigators in Sweden with input and funding from
GlaxoSmithKline.Analysis
A sample size of 300 patients was calculated for the
randomised phase of the study on the basis of 80% power to
detect a difference of 20% between any pair of treatment
groups (i.e. SFC vs FP or SAL monotherapies) in the
percentage of patients requiring an increase in study
medication in any 1 year. All analyses for the open phase
were performed after unblinding of the randomised phase.
The requirement for an increase in controller medica-
tion was a key endpoint. A KaplaneMeier survival analysis,
stratified by randomised treatment, was produced for the
time to first increase in medication level from random-
isation, and a log rank test was performed. Patients who
withdrew prior to the end of the 3 year treatment period
were censored at the time at which they withdrew.
Summaries of airway responsiveness, clinic lung func-
tion, daily PEF, and symptom and rescue-free days and
nights were produced for each visit by the treatments
received during the study and for all patients combined.
The proportion of symptom and rescue-free days were
investigated using logistic regression. The effects of base-
line covariates (age, sex, baseline percent predicted FEV1,
and previous inhaled corticosteroid usage) were included.
Log transformed PC20 methacholine was compared using
analysis of covariance (ANCOVA) with the baseline cova-
riates described above.
To investigate predictors of achieving different aspects
of asthma control, logistic regression models were fitted to
investigate the effect of age (<30, 30e50, >50 years),
asthma duration (<6, 6e10, >10 years), atopy (unknown,
yes, no), gender, smoking history (never, former, current)
and randomised treatment (SAL, FP, SFC) on whether or not
patients achieved either 100% symptom-free days, 100%
symptom-free nights or a PC20 > 8 mg/mL. Symptom-free
days and nights were assessed over the 2 weeks prior to
each clinic visit and PC20 was measured at the annual clinic
visit or at the final visit for those who withdrew from the
study. Patients who were given an increase in study medi-
cation were regarded as ‘‘treatment failures’’ for the
purposes of all logistic regression analyses. Patients who
withdrew were removed from the analysis.
Results
Baseline characteristics and disposition
Of the 282 patients randomised to study treatment, 229
(81%) completed the 3-year study. The treatment groups
were well matched (Fig. 2) and baseline characteristics of
the patients randomised to treatment have been presented
previously.16 Overall the mean FEV1 was 93% predicted and
99% had a PC20 to methacholine of <8 mg/mL; the
geometric mean PC20 was 0.57 mg/mL (coefficient of vari-
ation [cv] 282).
Summary of first year efficacy
Fewer patients required an increase in study medication
during the first year of the study with SFC (10.5%) compared
with either FP (34.8%) or SAL (61.1%) (p < 0.001).
Figure 2 Patient disposition.
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with SFC (4.2%), compared with FP (17.4%; p < 0.01) or SAL
(40%; p < 0.001) during the first year. SFC also improved
AHR to a significantly greater extent than FP (methacholine
PC20Z 1.8 mg/mL versus 1.1 mg/mL; p < 0.05) or SAL
(methacholine PC20Z 1.8 mg/mL versus 0.7 mg/mL;
p < 0.001).16
Efficacy
To achieve and maintain good control of asthma, increases
in treatment at any time during the 3-year study were
required by 144 patients (24 [25%] of those initially rando-
mised to SFC, 43 [47%] of those initially treated with FP and
77 [81%] with SAL). By the end of the study 73% (168/229) of
the subjects remaining in the study were receiving SFC to
maintain control of their asthma, compared with 21%
(49/229) receiving FP and 5% (12/229) receiving SAL
(Fig. 3). Logistic regression analysis showed that the odds
ratio for requiring increased treatment were 2.66 (95% CI
1.43, 4.96; pZ 0.002) for the FP group and 9.38 (95% CI
4.68, 18.80; p < 0.0001) for the SAL group compared with
the SFC group. The odds ratio of increasing treatment washigher (odds ratio 2.55) for a patient who had used inhaled
corticosteroids prior to the study relative to a patient who
had no such use.
The time until 25% of patients first required an
increase in study medication was estimated to be
6 months (95% CI 3.0, 9.0) for patients initially treated
with SAL compared to 12 months (95% CI 11.7, 14.9) for
those treated with FP and 21 months (95% CI 17.3, no
upper limit) for SFC (Fig. 4). Log rank analysis showed the
hazard ratio for a patient in the SAL group requiring an
increase in treatment was 5.70 (95% CI 3.74, 8.70;
p < 0.0001) compared to the SFC group and was 1.88 (95%
CI 1.21, 2.92; pZ 0.0049) in the FP group compared to
the SFC group. The probabilities of patients not requiring
an increase from their randomised medication at any time
during the 3 year treatment period were greater for SFC
(71%) than for FP (49%) or SAL (10%).
Logistic regression analyses demonstrated that the odds
for greater improvement of symptom-free nights for
patients with an asthma duration of <6 years were
approximately twice those for patients with an asthma
duration of >10 years (odds ratio 2.05, 95% CI 1.03, 4.07)
and the odds of achieving 100% symptom-free days were
Figure 3 Changes in treatment and dose throughout the
study.
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than for patients aged <30 years (odds ratio 3.69, 95% CI
1.11, 12.20). Asthma duration was also a predictor for
having a PC20 methacholine of >8 mg/mL (odds ratio for
asthma duration <6 years versus >10 years 2.83; 95% CI
1.15, 6.96). Compared with FP or SAL, treatment with SFC
was a predictor of success for achievement of symptom-
free nights but not symptom-free days or decreasing airway
hyperresponsiveness: odds ratios were 0.359 (95% CI 0.182,
0.710) and 0.304 (95% CI 0.155, 0.595), respectively for
symptom-free nights.
The various approaches to treatment led to overall
improvements in symptoms and lung function and
decreases in rescue medication use and airway hyper-
responsiveness at the end of the 3-year study period
(Table 1). ANCOVA analyses of PC20 methacholine and of
the mean percentage of symptom-free and rescue-free
days showed that there was no statistically significant
difference between any of the treatment groups at the end
of 3 years. Normal airway hyperresponsiveness was ach-
ieved in 31% (21/68) of patients treated with SFC and 33%
(14/43) of patients treated with FP after 3 years. These
data show that medication was being adjustedFigure 4 KaplaneMeier plot of time to first increase in
treatment from randomised study medication.appropriately by the physician to achieve asthma control
since similar levels of asthma control were being achieved
with all treatment regimens.
Since results were similar across treatment groups at the
end of the study, indicating that all patients had a similar
level of asthma control, data from all treatment groups
were combined so that the rate of change of the
improvements over the 3-year period can be shown (Fig. 5).
Symptoms and use of rescue medication improved first,
followed rapidly by PEF, and the greatest improvements in
these assessments were generally within the first year of
treatment. However, airway hyperresponsiveness
continued to improve throughout the study and was
continuing to improve at the end of 3 years. At 3 years
58/229 patients (25%) had normal airway responsiveness
(PC20 > 8 mg/mL).
Safety assessments
The number of patients experiencing AEs during treatment
in the double-blind phase of the study was similar between
the treatment groups; 96% in the SFC group, 97% in the FP
group and 95% in the salmeterol group. The most commonly
occurring event was an upper respiratory tract infection
with 88% of patients treated with SFC, 87% with FP and 75%
with salmeterol reporting this event. Other common
adverse events included asthma, viral infection, muscular
skeletal pain and gastroenteritis. All were evenly distrib-
uted across treatment groups. Nineteen serious adverse
events were reported during the study, none of which was
considered to be related to study medication. Hoarsness/
dysphonia was the most common adverse event which was
considered by the investigator to be drug-related, occurring
in 9% of patients treated with SFC, 5% with FP and 15% with
SAL. No deaths were reported during the study. Mean
morning serum cortisol was 433 nmol/L at randomisation
and 428 nmol/L after 3 years for patients treated with SFC,
464 and 435 nmol/L for those treated with FP, and
370 nmol/L at randomisation and 452 nmol/L after 3 years
for those treated with SAL. The high total incidence of
adverse event reports was attributed to the long study
duration and overall all study treatments were well
tolerated.
Discussion
This is the first study to assess clinical control of asthma and
assessment of airway hyperresponsiveness over 3 years. It
was performed by a single study team in four closely-
associated clinics in northern Sweden to minimise vari-
ability and was designed to reflect normal clinical practice
as closely as possible. Overall follow up and patient
compliance with their medication in this study was excel-
lent with little variability between the treatments. The
results demonstrate that asthma control is achievable with
physician-directed changes in medication following clinical
assessment of asthma.
The first year of the study demonstrated that patients
treated with SFC experienced fewer exacerbations and
achieved greater improvements in AHR compared to those
treated with FP or SAL alone. Significantly fewer patients in
Table 1 Lung function, symptoms, and rescue medication use at baseline and end of study: number (%) of patients with
normal/near normal values.
Outcome variable Time in study SFC n (%) FP n (%) FP/SFC n (%) SAL n (%)a SAL/FP n (%)b SAL/SFC n (%)
Total number
of patientsc
Randomisation 95 92 e 95 e e
After 3 years 76 46 30 12 3 62
FEV1  80% predicted Randomisation 76 (80) 76 (83) e 80 (84) e e
After 3 years 59 (78) 43 (93) 22 (73) 12 (100) 2 (67) 49 (79)
PEF  80% predicted Randomisation 93 (98) 91 (99) e 90 (95) e e
After 3 years 74 (97) 46 (100) 26 (87) 12 (100) 2 (67) 58 (94)
100% symptom-free days Randomisation 6 (6) 7 (8) e 10 (11) e e
After 3 years 32 (42) 18 (39) 10 (33) 7 (58) 1 (33) 22 (35)
100% symptom-free nights Randomisation 41 (43) 44 (48) e 48 (51) e e
After 3 years 55 (72) 29 (63) 16 (53) 12 (100) 0 (0) 36 (58)
100% rescue
medication-free days
Randomisation 20 (21) 18 (20) e 16 (17) e e
After 3 years 41 (54) 25 (54) 11 (37) 8 (67) 1 (33) 27 (44)
100% rescue
medication-free nights
Randomisation 61 (64) 64 (70) e 56 (59)
After 3 years 60 (79) 37 (80) 18 (60) 12 (100) 1 (33) 43 (69)
SFC, salmeterol/FP throughout the study; FP, FP throughout the study; FP/SFC, FP changing to salmeterol/FP during the study; SAL,
salmeterol throughout the study; SAL/SFC, salmeterol changing to salmeterol/FP during the study; SAL/FP, salmeterol changing to FP
during the study.
a Includes one patient who was treated with salmeterol/FP for 6 months during the study but changed back to salmeterol alone.
b Patients who experienced tremor on SAL were changed from FP to SFC.
c Not all patients had all assessments made at each timepoint. Patients with missing assessments were assumed not to have normal/
near normal values.
Asthma control in ‘‘real life’’ 353the SFC group required an increase in study medication to
achieve effective asthma control during the first year
compared to FP or SAL alone.16 After 3 years 73% of the
patients remaining in the study were treated with SFC to
maintain control and patients who received this treatment
initially were less likely to require an increase in medica-
tion than those treated with FP or SAL alone. This finding is
consistent with those of the GOAL study15 which used highly
rigorous composite measures of control based on the
guidelines. In the present study, 21% of patients were able
to achieve control with FP and only 5% on SAL alone the
results at 3 years. The very small number of patients who
were controlled on SAL alone confirms recent guideline
recommendations that this treatment should not be used as
a monotherapy for the treatment of asthma.
In contrast to previous studies such as GOAL, this study
did not include a rigorous definition of asthma control
based on a careful analysis of multiple study measure-
ments. We intended the study to reflect usual clinical
practice as closely as possible and the investigating physi-
cians were able to apply the concept of good asthma
control as outlined in the GINA guidelines by applying their
clinical judgement when making a decision to change
patients’ medication in the study. We were able to ensure
that this judgment was consistent throughout the study
which was conducted by the same small team within
a localised region.
It was possible to change patients’ medication and to
increase or, after the first year, to decrease dosages at the
clinic visits during this study. These adjustments could
occur on more than one occasion for an individual patient.
Comparison of lung function and clinical endpoints between
treatments at the end of the 3-year period confirmed that
the aims of treatment had been achieved in the large
majority of patients and that the majority achieved clinicalcontrol of asthma on the combination SFC. This ‘‘real-life’’
trial is consistent with the results of the GOAL study and
demonstrates its applicability to every day clinical
practice.
The clinical improvements in the study were associated
with improvements in airway hyperresponsiveness. At the
end of 3 years, 31% of patients treated with SFC no longer
had evidence of airway hyperreactivity. Airway hyper-
responsiveness is associated with inflammation in both
symptomatic and non-symptomatic individuals.23 Green
and colleagues demonstrated improvements in airway
hyperresponsiveness in asthmatic patients treated to
normalise sputum eosinophil counts; this treatment
strategy was also associated with a lower exacerbation rate
than in patients in a clinical management group.24 The
importance of controlling airway inflammation to reduce
eosinophilic exacerbations was confirmed recently25 and
Sont and colleagues26 have shown that patients treated to
control airway hyperresponsiveness have a decrease in
exacerbation rate compared with those treated to control
clinical parameters only. Thus normalising airway hyper-
responsiveness may be important for prevention of exca-
cerbations and long-term prognosis in asthma.
This study confirms and extends earlier work which has
shown that the time course for different measures of
response to treatment appears to vary, with symptoms and
lung function improving relatively quickly but airway
hyperresponsiveness continues to improve over many
months.8,27,28 We also showed relatively rapid effects on
symptoms and lung function. Ward and colleagues29 showed
that although improvements in lung function had peaked by
3 months with treatment with inhaled fluticasone propio-
nate, airway hyperresponsiveness continued to improve
throughout the year-long treatment period. We demon-
strated that airway hyperresponsiveness continued to
Figure 5 Time course for changes in lung function, symp-
toms, rescue use and airway hyperresponsiveness. (a) Mean
morning and evening PEF (L/min). (b) >75% Rescue and
symptom-free days and nights (proportion of patients). (c)
Geometric mean PC20 (mg/mL).
354 B. Lundba¨ck et al.improve over 3 years. Bateman and colleagues concluded
that treatment should be continued until composite control
is achieved, rather than individual outcomes. Months and
even years of continued treatment and clinical manage-
ment to maintain control of asthma may be necessary
to ensure improvement of underlying airway
hyperresponsiveness.
In summary, we have shown that it is possible for the
majority of patients to achieve and maintain control of
asthma over a 3-year period with physician-driven medi-
cation changes in a study that was close to usual clinical
practice. Patients treated with SFC were more likely to
achieve control than patients treated with FP or SAL alone.
There were improvements in clinical endpoints and in
airway hyperresponsiveness. Airway hyperresponsiveness
continued to improve throughout the study, emphasisingthe importance of continuing regular controller treatment
even when clinical endpoints have been normalised.
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